News | August 03, 2021
Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The first batch will be shipped to the Gamaleya Center for the quality control
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Subscribe To Our Newsletter & Stay Updated
